TGFβ:: the molecular Jekyll and Hyde of cancer

被引：1074

作者：

Bierie, Brian

Moses, Harold L.

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 07期

关键词：

D O I：

10.1038/nrc1926

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Transforming growth factor-beta (TGF beta) signalling regulates cancer through mechanisms that function either within the tumour cell itself or through host-tumour cell interactions. Studies of tumour-cell-autonomous TGF beta effects show clearly that TGF beta signalling has a mechanistic role in tumour suppression and tumour promotion. In addition, factors in the tumour microenvironment, such as fibroblasts, immune cells and the extracellular matrix, influence the ability of TGF beta to promote or suppress carcinoma progression and metastasis. The complex nature of TGF beta signalling and crosstalk in the tumour microenvironment presents a unique challenge, and an opportunity to develop therapeutic intervention strategies for targeting cancer.

引用

收藏

页码：506 / 520

页数：15

相关论文

共 159 条

[51]

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling [J].

Ge, RR ;

Rajeev, V ;

Subramanian, G ;

Reiss, KA ;

Liu, D ;

Higgins, L ;

Joly, A ;

Dugar, S ;

Chakravarty, J ;

Henson, M ;

McEnroe, G ;

Schreiner, G ;

Reiss, M .

BIOCHEMICAL PHARMACOLOGY, 2004, 68 (01) :41-50

[52]

TRANSFORMING GROWTH FACTOR-BETA(1) (TGF-BETA(1) CONTROLS EXPRESSION OF MAJOR HISTOCOMPATIBILITY GENES IN THE POSTNATAL MOUSE - ABERRANT HISTOCOMPATIBILITY ANTIGEN EXPRESSION IN THE PATHOGENESIS OF THE TGF-BETA(1) NULL MOUSE PHENOTYPE [J].

GEISER, AG ;

LETTERIO, JJ ;

KULKARNI, AB ;

KARLSSON, S ;

ROBERTS, AB ;

SPORN, MB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (21) :9944-9948

[53]

GIANNOULL CC, 2005, CELL SIGNAL 1214

[54]

Oligomeric structure of type I and type II transforming growth factor β receptors:: Homodimers form in the ER and persist at the plasma membrane [J].

Gilboa, L ;

Wells, RG ;

Lodish, HF ;

Henis, YI .

JOURNAL OF CELL BIOLOGY, 1998, 140 (04) :767-777

[55]

Go C, 1999, CANCER RES, V59, P2861

[56]

Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFβRII [J].

Go, C ;

He, W ;

Zhong, L ;

Li, P ;

Huang, J ;

Brinkley, BR ;

Wang, XJ .

ONCOGENE, 2000, 19 (32) :3623-3631

[57]

Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease [J].

Gorelik, L ;

Flavell, RA .

IMMUNITY, 2000, 12 (02) :171-181

[58]

Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells [J].

Gorelik, L ;

Flavell, RA .

NATURE MEDICINE, 2001, 7 (10) :1118-1122

[59]

Transforming growth factor-β in T-cell biology [J].

Gorelik, L ;

Flavell, RA .

NATURE REVIEWS IMMUNOLOGY, 2002, 2 (01) :46-53

[60]

Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-b receptor exhibit impaired mammary development and enhanced mammary tumor formation [J].

Gorska, AE ;

Jensen, RA ;

Shyr, Y ;

Aakre, ME ;

Bhowmick, NA ;

Moses, HL .

AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (04) :1539-1549

← 1 2 3 4 5 6 7 8 9 10 →